Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. monthly Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E22.45 EPS (ttm)25.83 Insider Own0.90% Shs Outstand109.60M Perf Week-3.32%
Market Cap60.19B Forward P/E16.50 EPS next Y35.15 Insider Trans-44.56% Shs Float101.66M Perf Month4.01%
Income2.98B PEG1.91 EPS next Q7.04 Inst Own90.00% Short Float2.02% Perf Quarter-9.04%
Sales8.00B P/S7.53 EPS this Y-10.80% Inst Trans-0.09% Short Ratio2.36 Perf Half Y5.90%
Book/sh82.64 P/B7.02 EPS next Y23.13% ROA20.30% Target Price678.33 Perf Year89.62%
Cash/sh30.29 P/C19.14 EPS next 5Y11.77% ROE27.90% 52W Range299.22 - 664.64 Perf YTD54.42%
Dividend- P/FCF24.82 EPS past 5Y44.00% ROI16.10% 52W High-12.76% Beta0.40
Dividend %- Quick Ratio1.80 Sales past 5Y22.80% Gross Margin88.20% 52W Low93.77% ATR17.73
Employees8100 Current Ratio2.10 Sales Q/Q23.70% Oper. Margin34.60% RSI (14)47.29 Volatility2.40% 3.15%
OptionableYes Debt/Eq0.24 EPS Q/Q351.70% Profit Margin37.30% Rel Volume0.65 Prev Close575.73
ShortableYes LT Debt/Eq0.08 EarningsNov 05 BMO Payout0.00% Avg Volume868.20K Price579.81
Recom2.10 SMA20-0.85% SMA50-1.18% SMA2007.69% Volume562,933 Change0.71%
Oct-05-20Upgrade Cantor Fitzgerald Neutral → Overweight $690
Aug-20-20Downgrade The Benchmark Company Buy → Hold
Jul-09-20Upgrade SunTrust Hold → Buy $400 → $750
May-26-20Upgrade Wells Fargo Equal Weight → Overweight $559 → $734
Apr-28-20Downgrade Citigroup Buy → Neutral $540 → $575
Apr-17-20Upgrade The Benchmark Company Hold → Buy $655
Apr-08-20Initiated The Benchmark Company Hold
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $530
Feb-26-20Upgrade Canaccord Genuity Hold → Buy $550
Feb-26-20Downgrade Robert W. Baird Outperform → Neutral $410
Feb-25-20Upgrade Jefferies Hold → Buy $355 → $492
Feb-11-20Upgrade Argus Hold → Buy $430
Dec-24-19Initiated Raymond James Mkt Perform
Dec-16-19Downgrade Evercore ISI Outperform → In-line
Dec-13-19Upgrade Credit Suisse Neutral → Outperform $400
Nov-12-19Initiated SunTrust Hold $360
Nov-07-19Upgrade Citigroup Neutral → Buy $340 → $420
Oct-17-19Resumed BofA/Merrill Neutral $325
Sep-23-19Upgrade Guggenheim Neutral → Buy $355 → $403
Oct-23-20 04:33PM  
03:30PM  
10:01AM  
06:30AM  
06:08AM  
Oct-22-20 03:34PM  
11:22AM  
07:07AM  
Oct-21-20 06:41PM  
04:34PM  
12:00PM  
Oct-20-20 03:49PM  
07:40AM  
Oct-19-20 04:32PM  
02:40PM  
01:35PM  
10:45AM  
10:09AM  
10:00AM  
09:55AM  
Oct-18-20 12:08PM  
Oct-16-20 04:57PM  
03:38PM  
03:36PM  
01:53PM  
10:01AM  
07:59AM  
06:26AM  
Oct-15-20 04:31PM  
03:19PM  
01:05PM  
10:29AM  
10:19AM  
08:03AM  
06:46AM  
Oct-14-20 10:44PM  
10:18PM  
05:42PM  
04:44PM  
04:29PM  
10:10AM  
Oct-13-20 11:48PM  
09:42PM  
05:03PM  
04:24PM  
03:30PM  
03:20PM  
11:35AM  
11:29AM  
05:46AM  
04:41AM  
12:59AM  
Oct-12-20 05:49PM  
05:23PM  
04:45PM  
04:17PM  
02:45PM  
09:46AM  
09:31AM  
08:31AM  
07:20AM  
Oct-11-20 11:42PM  
08:05PM  
07:28AM  
06:15AM  
06:07AM  
Oct-10-20 08:39AM  
06:25AM  
Oct-09-20 11:29PM  
08:43PM  
05:16PM  
04:26PM  
04:15PM  
03:51PM  
02:09PM  
12:37PM  
11:54AM  
11:00AM  
10:12AM  
10:02AM  
09:04AM  
Oct-08-20 08:44PM  
07:31PM  
04:28PM  
04:14PM  
03:35PM  
03:21PM  
02:15PM  
02:09PM  
01:45PM  
01:08PM  
12:56PM  
12:35PM  
12:26PM  
12:25PM  
12:08PM  
11:57AM  
11:33AM  
10:32AM  
10:13AM  
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MURPHY ANDREW JEVP ResearchOct 22Option Exercise38.565,185199,92647,136Oct 23 04:02 PM
McCourt MarionSVP CommercialOct 05Option Exercise342.931,000342,93014,963Oct 06 04:07 PM
GOLDSTEIN JOSEPH LDirectorOct 05Option Exercise520.019,2124,790,33214,855Oct 06 04:09 PM
McCourt MarionSVP CommercialOct 05Sale600.001,000600,00013,963Oct 06 04:07 PM
GOLDSTEIN JOSEPH LDirectorOct 05Sale600.009,2125,527,2005,643Oct 06 04:09 PM
RYAN ARTHUR FDirectorOct 01Sale558.1310055,81328,343Oct 05 04:13 PM
BROWN MICHAEL SDirectorSep 22Option Exercise378.775,0901,927,9175,733Sep 23 04:01 PM
BROWN MICHAEL SDirectorSep 22Sale552.361,000552,3609,349Sep 23 04:01 PM
BROWN MICHAEL SDirectorSep 22Sale552.365,0902,811,512643Sep 23 04:01 PM
GOLDSTEIN JOSEPH LDirectorSep 22Sale552.362011,0475,643Sep 23 04:00 PM
GOLDSTEIN JOSEPH LDirectorSep 21Option Exercise376.7616,5746,244,37222,217Sep 23 04:00 PM
GOLDSTEIN JOSEPH LDirectorSep 21Sale549.8616,5549,102,4465,663Sep 23 04:00 PM
RYAN ARTHUR FDirectorSep 01Sale604.5810060,45828,443Sep 03 04:18 PM
SING GEORGE LDirectorAug 31Sale612.0610,0006,120,55554,415Aug 31 04:36 PM
LAROSA JOSEPH JEVP General Counsel and SecretAug 31Sale615.044,6722,873,46714,438Aug 31 04:37 PM
POON CHRISTINE ADirectorAug 28Option Exercise28.4440,0001,137,55041,433Aug 31 04:35 PM
POON CHRISTINE ADirectorAug 28Sale601.2240,00024,048,7151,433Aug 31 04:35 PM
LAROSA JOSEPH JEVP General Counsel and SecretAug 27Option Exercise52.0310,000520,30021,241Aug 31 04:37 PM
SING GEORGE LDirectorAug 25Option Exercise273.6712,7503,489,29397,165Aug 27 04:23 PM
Van Plew Daniel PEVP & General Mgr Industrial OAug 25Sale610.8927,10916,560,73820,001Aug 27 04:21 PM
SING GEORGE LDirectorAug 25Sale612.001,000612,0003,700Aug 27 04:23 PM
SING GEORGE LDirectorAug 25Sale607.2832,75019,888,51864,415Aug 27 04:23 PM
SING GEORGE LDirectorAug 24Option Exercise177.8210,0371,784,779104,452Aug 24 06:13 PM
SING GEORGE LDirectorAug 24Sale593.6320,03711,894,57784,415Aug 24 06:13 PM
SING GEORGE LDirectorAug 21Option Exercise117.249,9631,168,071114,078Aug 24 06:13 PM
SING GEORGE LDirectorAug 21Sale605.1219,96312,080,04094,415Aug 24 06:13 PM
GOLDSTEIN JOSEPH LDirectorAug 21Sale617.181,000617,1805,643Aug 24 05:19 PM
Van Plew Daniel PEVP & General Mgr Industrial OAug 20Option Exercise179.1375,00013,434,75095,001Aug 24 04:47 PM
SING GEORGE LDirectorAug 20Option Exercise57.1110,000571,100114,415Aug 24 06:13 PM
McCourt MarionSVP CommercialAug 20Option Exercise342.931,000342,93014,963Oct 06 04:07 PM
SING GEORGE LDirectorAug 20Sale616.9121,00012,955,042104,415Aug 24 06:13 PM
McCourt MarionSVP CommercialAug 20Sale612.151,000612,15013,963Oct 06 04:07 PM
VAGELOS P ROYDirectorAug 11Sale602.9433,46020,174,35550,192Aug 13 04:02 PM
Landry Robert EEVP Finance CFOAug 04Sale654.46696455,50423,973Aug 05 05:07 PM
RYAN ARTHUR FDirectorAug 03Sale641.9310064,19328,543Aug 05 05:09 PM
Landry Robert EEVP Finance CFOJul 21Sale647.58391253,20424,669Jul 22 04:30 PM
Fenimore Christopher R.VP ControllerJul 21Sale642.043,7092,381,31717,501Jul 22 04:31 PM
Fenimore Christopher R.VP ControllerJul 20Option Exercise156.0112,2241,907,01525,277Jul 22 04:31 PM
Landry Robert EEVP Finance CFOJul 20Option Exercise491.438,5004,177,16029,671Jul 22 04:30 PM
MURPHY ANDREW JEVP ResearchJul 14Sale633.482,3801,507,67741,951Jul 15 04:51 PM
MURPHY ANDREW JEVP ResearchJul 14Sale623.893,9292,451,27744,331Jul 15 04:51 PM
Landry Robert EEVP Finance CFOJul 14Sale640.50579370,85023,973Jul 14 04:17 PM
MURPHY ANDREW JEVP ResearchJul 13Option Exercise30.6313,000398,19054,951Jul 15 04:51 PM
MURPHY ANDREW JEVP ResearchJul 13Sale628.508,0005,028,02241,951Jul 15 04:51 PM
Landry Robert EEVP Finance CFOJul 09Option Exercise399.663,0001,198,98026,973Jul 13 04:28 PM
Landry Robert EEVP Finance CFOJul 08Sale639.661,160742,01123,973Jul 09 04:29 PM
SING GEORGE LDirectorJul 07Option Exercise33.427,500250,650122,915Jul 08 04:16 PM
Zoghbi Huda YDirectorJul 07Option Exercise391.921,706668,6162,349Jul 08 04:14 PM
Landry Robert EEVP Finance CFOJul 07Option Exercise524.4712,5006,555,85033,973Jul 09 04:29 PM
SING GEORGE LDirectorJul 07Sale650.163,0001,950,474400Jul 08 04:16 PM
SING GEORGE LDirectorJul 07Sale650.007,5004,875,000115,415Jul 08 04:16 PM
Zoghbi Huda YDirectorJul 07Sale650.001,7061,108,900643Jul 08 04:14 PM
BROWN MICHAEL SDirectorJul 01Option Exercise413.333,6131,493,3614,256Jul 02 04:02 PM
BROWN MICHAEL SDirectorJul 01Sale607.623,6132,195,342643Jul 02 04:02 PM
RYAN ARTHUR FDirectorJul 01Sale609.7010060,97028,643Jul 02 04:01 PM
SING GEORGE LDirectorJun 29Sale608.913,0001,826,7211,400Jun 29 04:08 PM
Landry Robert EEVP Finance CFOJun 29Sale612.57400245,02923,973Jun 30 04:02 PM
Landry Robert EEVP Finance CFOJun 23Sale631.27512323,21224,373Jun 24 04:03 PM
Landry Robert EEVP Finance CFOJun 22Option Exercise555.678,9004,945,46333,273Jun 24 04:03 PM
Bassler Bonnie LDirectorJun 19Option Exercise391.922,5591,002,9233,202Jun 22 04:18 PM
Bassler Bonnie LDirectorJun 19Sale630.022,5591,612,211643Jun 22 04:18 PM
Fenimore Christopher R.VP ControllerJun 16Sale590.893,5562,101,21515,277Jun 17 04:02 PM
Fenimore Christopher R.VP ControllerJun 15Option Exercise47.079,406442,74220,323Jun 17 04:02 PM
Zoghbi Huda YDirectorJun 11Option Exercise391.921,706668,6162,349Jun 12 04:03 PM
Zoghbi Huda YDirectorJun 11Sale625.001,7061,066,250643Jun 12 04:03 PM
Landry Robert EEVP Finance CFOJun 11Sale612.08988604,73124,373Jun 12 04:01 PM
Landry Robert EEVP Finance CFOJun 10Option Exercise272.703,500954,45027,873Jun 12 04:01 PM
Zoghbi Huda YDirectorJun 10Option Exercise391.921,706668,6162,349Jun 12 04:03 PM
Zoghbi Huda YDirectorJun 10Sale610.241,7061,041,068643Jun 12 04:03 PM
Landry Robert EEVP Finance CFOJun 09Sale608.014,2712,596,79224,373Jun 10 04:04 PM
GOLDSTEIN JOSEPH LDirectorJun 08Option Exercise413.3310,8384,479,67117,481Jun 09 04:05 PM
Landry Robert EEVP Finance CFOJun 08Option Exercise272.7015,5004,226,85029,860Jun 10 04:04 PM
GOLDSTEIN JOSEPH LDirectorJun 08Sale592.9510,8386,426,3626,643Jun 09 04:05 PM
Bassler Bonnie LDirectorJun 05Option Exercise391.922,5591,002,9233,202Jun 05 04:15 PM
Bassler Bonnie LDirectorJun 05Sale600.002,5591,535,400643Jun 05 04:15 PM
RYAN ARTHUR FDirectorJun 01Sale603.2310060,32328,743Jun 02 04:04 PM
SING GEORGE LDirectorMay 29Sale596.511,000596,5102,400Jun 01 04:08 PM
GOLDSTEIN JOSEPH LDirectorMay 28Sale578.941,000578,9406,643Jun 01 04:02 PM
SING GEORGE LDirectorMay 28Sale579.001,000579,0002,900Jun 01 04:08 PM
VAGELOS P ROYChairman of the BoardMay 21Sale577.49783452,178307,749May 22 06:21 PM
VAGELOS P ROYChairman of the BoardMay 21Sale564.37148,81183,984,786308,532May 22 06:21 PM
VAGELOS P ROYChairman of the BoardMay 20Option Exercise30.63312,5009,571,875497,063May 22 06:21 PM
LAROSA JOSEPH JEVP General Counsel and SecretMay 15Sale572.008,3804,793,36014,438May 15 04:03 PM
LAROSA JOSEPH JEVP General Counsel and SecretMay 14Option Exercise59.2018,3111,084,01132,749May 15 04:03 PM
SING GEORGE LDirectorMay 13Option Exercise33.425,000167,100120,415May 13 09:00 PM
SING GEORGE LDirectorMay 13Sale580.005,0002,900,000115,415May 13 09:00 PM
SCHLEIFER LEONARD SPresident & CEOMay 12Sale569.22150,92285,908,042474,499May 13 09:01 PM
SCHLEIFER LEONARD SPresident & CEOMay 11Option Exercise30.63312,5009,571,875722,368May 13 09:01 PM
SING GEORGE LDirectorMay 11Sale575.00850488,7502,150May 13 09:00 PM
STAHL NEILEVP Research and DevelopmentMay 11Sale569.525,3053,021,28911,380May 11 04:39 PM
STAHL NEILEVP Research and DevelopmentMay 08Option Exercise52.0312,500650,37523,880May 11 04:39 PM
Zoghbi Huda YDirectorMay 07Option Exercise391.925,1182,005,8475,761May 08 04:03 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 07Sale564.3239,58322,337,30628,251May 08 04:04 PM
Zoghbi Huda YDirectorMay 07Sale566.525,1182,899,461643May 08 04:03 PM
BROWN MICHAEL SDirectorMay 07Sale562.001,8091,016,658643May 07 04:14 PM
BROWN MICHAEL SDirectorMay 06Option Exercise371.985,4702,034,7395,863May 07 04:14 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 06Option Exercise52.0385,5794,452,67596,051May 08 04:04 PM
Tessier-Lavigne MarcDirectorMay 06Option Exercise177.8215,0002,667,30016,830May 08 04:03 PM
RYAN ARTHUR FDirectorMay 06Option Exercise373.6750,12418,729,67078,967May 07 06:22 PM
RYAN ARTHUR FDirectorMay 06Sale550.8850,12427,612,50928,843May 07 06:22 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.